Recently, the Jiangsu Provincial Health and Family Planning Commission and other relevant units decided to hold the signing ceremony of the multi-center clinical trial of ACTL targeted anti-tumor cell immune technology in Nanjing, Jiangsu Province on March 13, 2016.

ACTL technology Jiangsu multi-center trial In order to further prove the objective effectiveness of ACTL immunotherapy for non-small cell lung adenocarcinoma, the Jiangsu Provincial Health and Family Planning Commission decided to lead the Jiangsu Provincial People’s Hospital to carry out this multi-center in cooperation with 14 hospitals in the province. Research projects. This parallel, randomized, multi-center clinical trial will strictly follow the national clinical trial standards. It is expected to be completed in at least one year and cost nearly 100 million yuan.

ACTL targeted anti-tumor cellular immune technology is a new type of biological therapy based on multiple disciplines such as molecular biology, oncology, and immunology. This technology can remove tumor foci, significantly reduce the level of serum tumor markers, and is of great help in preventing recurrence and prolonging patient survival. At the same time, the treatment can also reverse the patient's resistance to small molecule targeted drugs.

ACTL is a targeted cellular immunotherapy that only attacks tumor cells without harm to other organisms. It has high safety and low side effects. The treatment route is intravenous injection and reinfusion, with little trauma and no pain. In other words, the treatment of tumors with ACTL technology will not cause damage to the normal cells and tissues of the human body, and it is a true "green therapy".

The ACTL technology research team is full of confidence in the technology and is full of expectations for the results of this multi-center experiment.

This clinical trial is my country's first multi-center clinical study in the field of targeted immune cell therapy. It is a breakthrough project in the field of cell therapy, especially anti-tumor cell immunotherapy.